Yüklüyor......
Novel antidotes for target specific oral anticoagulants
Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing cl...
Kaydedildi:
| Yayımlandı: | Exp Hematol Oncol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4570637/ https://ncbi.nlm.nih.gov/pubmed/26380149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-015-0020-3 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|